None listed
Conditions
Interventions
group A (alfentanil combined with remimazolam):Alfentanil (5~10µg/kg) was administered slowly intravenously followed by a loading dose of 5mg slowly intravenously with remimazolam for 1 minute
group B (alfentanil combined with propofol):Alfentanil (5~10µg/kg) is slowly injected intravenously first, and then propofol is slowly injected intravenously
Sponsors
Meizhou People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Voluntary participation in this clinical trial and signing the informed consent form; 2.aged 18 to 65 years old, with ASA classification of I to II, no history of severe heart, lung, liver or kidney diseases before surgery, no history of upper respiratory tract infection recently, no history of drug allergy, and no mental system diseases.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of mental illness or long-term use of narcotic analgesics, sedatives or non-steroidal anti-inflammatory drugs; 2.opiate-dependent or opiate-tolerant individuals; 3.those with a history of cerebral infarction or brain injury; 4.and those with preoperative abnormalities in heart, lung, liver or kidney function, especially bradycardia and second-degree or higher atrioventricular block.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemodynamics: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and blood oxygen saturation (SpO2);Procedure time, Recovery time, Alertness time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions: bloating, pain, movement, memory issues, injection pain, respiratory depression, hypotension, dizziness, postoperative nausea and vomiting; | — |
Countries
China
Contacts
Public ContactYuting Zhong
Meizhou People's Hospital
Outcome results
None listed